Umi No Shizuku vs NatureMedic: Which Fucoidan Is Right for You?

Dai Tran, PharmD, MBA, B.S.

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist

Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience

If you've been researching Japanese Fucoidan supplements, you've likely come across two names repeatedly: Umi No Shizuku and NatureMedic®. Both are authentic Japanese brands with strong reputations — but they're not the same product, and the right choice depends on your health goals, budget, and preferences. As the pharmacists who carry and personally review both lines, here's our honest side-by-side comparison.

Brand Overview

Capsule Comparison

Liquid Comparison

Umi No Shizuku — The Okinawan Classic

Umi No Shizuku (海の滴, meaning “Droplets of the Sea”) is produced in Okinawa — a region renowned for longevity and traditional seaweed consumption. It uses a dual-source fucoidan blend from Mozuku and Mekabu, two of the more clinically studied fucoidan species in the ingredient research literature.

• Available in three forms — capsule, liquid, and powder
• Pure fucoidan focus — no additional compounds, straightforward supplementation
• HFA (Japan Health and Nutrition Food Association) certified
• Okinawan heritage with long consumer history in Japan

NatureMedic® — The Combination Formula

NatureMedic® offers two distinct lines: Fucoidan 3-PLUS (triple-source fucoidan) and Fucoidan Powered with AHCC® (fucoidan + AHCC® combination). The 3-PLUS line adds a third fucoidan species (Fucus) to the Mozuku and Mekabu used in many Japanese fucoidan products. The AHCC® line adds Amino Up’s proprietary AHCC® compound, which has been independently studied in human trials for immune-related outcomes.

• Triple-source fucoidan — Mozuku, Mekabu, and Fucus; clinical evidence comparing triple- vs. dual-source fucoidan preparations has not been established
• AHCC® addition — fucoidan and AHCC® have each been studied independently in humans for immune-related markers; clinical synergy between the two in combination has not been established in human trials
• Produced with Amino Up — the original AHCC® developer

What Human Research Shows — Ingredient Evidence Summary

Fucoidan — Oncology Supportive Care — LIMITED / PRELIMINARY

• HUMAN RCT Tsai HL et al., 2017 (PMID: 28430159) — Low-molecular-weight fucoidan, metastatic colorectal cancer, n=54: Prospective double-blind RCT; fucoidan used alongside chemo-targeted treatment. Disease-control rate 92.8% vs 69.2% (P=0.026); overall survival, progression-free survival, objective response rate, adverse effects, and QOL were not significantly different between groups. Note: specific low-molecular-weight fucoidan preparation; does not establish Umi No Shizuku or NatureMedic® as cancer treatments.
• HUMAN RCT Ikeguchi M et al., 2011 (PMID: 22866084) — Fucoidan + FOLFOX/FOLFIRI, n=20: Randomized study; fucoidan vs. control during chemotherapy for advanced colorectal cancer. Fucoidan group showed reduced fatigue and longer treatment continuation; survival difference was not statistically significant. Evidence supports adjunct/supportive-care research, not anticancer efficacy.
• HUMAN RCT PMID: 37822243 — Fucoidan + neoadjuvant chemoradiotherapy, double-blind, n=87: Randomized, double-blind, placebo-controlled; 44 fucoidan / 43 placebo in locally advanced rectal cancer receiving concurrent chemoradiotherapy. Fucoidan was associated with better physical well-being at some time points and less skin rash/itching and fatigue. Overall FACT-C improvement was not statistically significant under the study’s threshold.
• SYSTEMATIC REVIEW PMID: 35628061 — Fucoidan in cancer supportive care, 4 studies, 118 participants: Reviewed 1 RCT and 3 quasi-experimental studies. Some studies suggested longer treatment/survival periods; effects on disease control, inflammation, nutrition, and fatigue were positive but not consistently significant. Literature was heterogeneous and small. Overall rating: evidence insufficient to establish fucoidan as an effective cancer treatment; supports classification as LIMITED / PRELIMINARY for oncology supportive care.
• HUMAN STUDY PMID: 28627320 — Fucoidan, inflammation, advanced cancer, n=20: Prospective open-label; 20 metastatic advanced cancer patients; oral fucoidan for ≥4 weeks; reductions in IL-1β, IL-6, and TNF-α after two weeks; QOL/fatigue generally stable. Authors explicitly called for larger blinded controlled trials. Exploratory evidence only.

Fucoidan — Drug Interaction — SAFETY / INTERACTION STUDY

• SAFETY / INTERACTION PMID: 28008779 — Fucoidan + letrozole/tamoxifen pharmacokinetics, 20 breast-cancer patients: In 20 breast-cancer patients taking letrozole (n=10) or tamoxifen (n=10), Undaria pinnatifida fucoidan 500 mg twice daily for 3 weeks did not significantly alter steady-state concentrations of letrozole, tamoxifen, 4-hydroxytamoxifen, or endoxifen. No significant toxicity signal was observed during the study period. This finding is preparation-, dose-, drug-, and duration-specific and should not be generalized to other fucoidan products, other cancer medications, or longer durations. Disclosure: one author was an employee of Marinova, the company that supplied the fucoidan used in the study. Patients on endocrine therapy, anticoagulants, or other cancer medications should still discuss all supplement use with their oncologist and pharmacist before starting.

AHCC® — Immune & HPV Evidence — LIMITED / SUPPORTIVE

• HUMAN RCT Smith JA et al., 2022 (PMID: 35814366) — AHCC + persistent high-risk HPV, Phase II RCT, n=41 completed — LIMITED / SUPPORTIVE HUMAN RCT EVIDENCE, preparation- and dose-specific: Randomized, double-blind, placebo-controlled Phase II study; 50 women >30 with persistent high-risk HPV >2 years. AHCC 3 g/day for 6 months. 14/22 (63.6%) in AHCC arm became HPV RNA/DNA negative; 9/14 maintained durable response 6 months after stopping. Placebo: 2/19 (10.5%) at 12 months. This remains essentially one modest-sized Phase II RCT plus earlier pilot evidence; it has not yet been independently replicated. Important dose caveat: trial used 3,000 mg/day of standalone AHCC® — substantially more than provided by typical servings of NatureMedic® AHCC® combination products (75 mg/capsule or 600 mg/packet). Clinical results from this trial should not be assumed to apply to finished combination products at different doses.
• HUMAN STUDY PMID: 30949451 — AHCC + HPV, pilot studies: Two small human pilot studies; 4/6 clearance with AHCC 3 g, 4/9 with AHCC 1 g. Preliminary findings preceding the later Phase II RCT; PMID 35814366 is the primary citation.
• HUMAN RCT Terakawa N et al., 2008 (PMID: 18791928) — AHCC immune modulation, healthy volunteers, n=21: Randomized double-blind placebo-controlled; AHCC 3 g/day for 4 weeks; increased circulating dendritic-cell numbers and selected functional measures. NK-cell activity was not significantly different between groups. This does not support claims of synergistic NK activation from fucoidan + AHCC® combination.
• HUMAN RCT Suknikhom W et al., 2017 (PMID: 28440968) — AHCC + platinum-based chemotherapy, ovarian/peritoneal cancer: Randomized; AHCC 3 g/day vs. placebo during 6 chemotherapy cycles; examined CD4+ and CD8+ T-cell levels. Again used 3 g/day standalone AHCC®; not directly transferable to combination finished products.
• HUMAN STUDY Ito T et al., 2014 (PMID: 24611562) — AHCC + chemotherapy adverse effects/QOL, advanced cancer: Evaluated AHCC in advanced-cancer patients receiving chemotherapy; examined chemotherapy-related adverse effects and quality of life. Supportive secondary evidence.

Pharmacist’s Recommendation by Patient Profile

• General immune maintenance: Either brand. Umi No Shizuku capsules offer simplicity and HFA certification.
• Maximum fucoidan dose: NatureMedic® 3-PLUS Liquid — 2,200 mg triple-source per packet.
• Fucoidan + AHCC® combination: NatureMedic® AHCC® — contains both ingredients that have been independently studied in humans; no finished-product oncology trial exists.
• HPV-related interest: AHCC® has a randomized Phase II trial for persistent high-risk HPV (PMID: 35814366), but it used 3,000 mg/day of standalone AHCC® and has not yet been independently replicated. NatureMedic® AHCC® products provide 75 mg/capsule or 600 mg/packet. Discuss dosing expectations with your pharmacist before purchase.
• Difficulty swallowing / elderly patients: Umi No Shizuku Powder — mix into any beverage.
• Cancer treatment or prescription medications: Consult your oncologist and pharmacist before starting any fucoidan or AHCC® product. A drug-interaction study (PMID: 28008779) found no significant pharmacokinetic interaction between a specific Undaria pinnatifida fucoidan preparation and letrozole or tamoxifen at 500 mg twice daily for 3 weeks; this finding does not generalize to other fucoidan products or cancer medications.

About Combining These Products

Combining multiple fucoidan products increases total fucoidan exposure. Controlled clinical trials have not established additional benefit or safety from combining Umi No Shizuku and NatureMedic® products. Patients undergoing cancer treatment or taking prescription medications should discuss all supplement use with their oncologist and pharmacist before combining products.

Related Clinical Insights Articles

• Fucoidan: What the Science Says — A Pharmacist’s Evidence Review →
• NatureMedic® Fucoidan + AHCC®: A Pharmacist’s Review of the Evidence →
• View Full Fucoidan Evidence Library →

Shop Fucoidan at Khang Pharmacy

We carry the full line of both brands — in-store in San Jose and shipping nationwide. Free PharmD consultation available.

(408) 622-8068 • 2451 S King Rd., Ste A1, San Jose, CA 95122
Shop all Fucoidan products →

† Ingredient-level human research (fucoidan preparations and AHCC®) cannot be assumed to apply to these specific finished products at the doses they provide. All clinical citations refer to specific ingredient preparations tested in defined populations; finished-product efficacy has not been established for Umi No Shizuku or NatureMedic® products.

Reviewed by:

Dai Tran, PharmD, MBA, B.S. • View full bio →

CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed • 10+ Years Clinical Experience

Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com